Polycythemia risk factors

Polycythemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polycythemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polycythemia risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polycythemia risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polycythemia risk factors
CDC on Polycythemia risk factors
Polycythemia risk factors in the news
Blogs on Polycythemia risk factors
Directions to Hospitals Treating Polycythemia
Risk calculators and risk factors for Polycythemia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Risk Factors

• One of the most common and most dangerous complications of polycythemia vera is thrombus formation. The risk factors are as follows:

• Women- usually younger at the time of diagnosis, have a higher risk of arterio-venous thrombosis.
• Mutation- higher burden of JAK2V617F allele
• Inflammatory markers- Pentraxins play an important role: increased hs-CRP and a lower PTX3 have a higher risk of thrombosis
• Presence of microparticles- responsible for decreased thrombin inhibition, increased CD41, and an increased chance of splenomegaly
• Neutrophil Extracellular Trap formations- NETosis and apoptosis